Author

A. Pagenstecher

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Schaefer· 2 shared C. Nimsky· 2 shared J. W. Bartsch· 2 shared O. Schilling· 2 shared A. Burchert· 1 shared A. Grote· 1 shared A. M. Hartmann· 1 shared A. Neubauer· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Schaefer

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Proteomic profiling of IDH-wildtype Glioblastoma Tissue and Serum uncovers prognostic Subtypes and Marker Candidates

T. Werner, A. Schaefer, M. Hennes, M. Cosenza Contreras, G. Espadas, E. Sabido, L. Cook, A. Pagenstecher, N. Pinter, T. Feilen, A. Grote, C. Nimsky, J. W. Bartsch, O. Schilling

This study identifies proteomic subtypes and recurrence patterns in IDH-wildtype glioblastoma using tissue and serum samples, revealing prognostic markers and proteomic plasticity in recurrent tumors.

bioRxiv · Feb 29, 2024 · PreprintCancer Biology

Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis

M. N. Stillger, C.-Y. Chen, Z. W. Lai, M. Li, A. Schaefer, A. Pagenstecher, C. Nimsky, J. W. Bartsch, O. Schilling

This study shows that calpain-2 expression in glioblastoma cells reduces TMZ-induced DNA damage and p53-dependent apoptosis, leading to chemoresistance.

bioRxiv · Oct 19, 2022 · PreprintCancer Biology

IRF4 deficiency vulnerates B cell progeny for leukemogenesis via somatically acquired Jak3 mutations conferring IL-7 hypersensitivity

D. Das Gupta, C. Paul, N. Samel, M. Bieringer, D. Staudenraus, F. Marini, H. Raifer, L. Menke, L. Hansal, B. Camara, E. Roth, P. Daum, M. Wanzel, M. Mernberger, A. Nist, , M. Lohoff

This study shows IRF4 deficiency leads to B cell leukemia via Jak3 mutations that increase IL-7 sensitivity, and JAK inhibition improves survival in a mouse model.

bioRxiv · Feb 16, 2022 · PreprintCancer Biology